Who are Eque-cel CAR-T Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Uplizna, BLINATUMOMAB, Blincyto, SCT800 and Daratumumab, REZ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eque-cel-car-t-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Eque-cel CAR-T Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eque-cel CAR-T Therapy (Eque-cel CAR-T Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy. Area: Oncology.

phase 2 CAR-T cell therapy CD19 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Eque-cel CAR-T Therapy (Eque-cel CAR-T Therapy) — Nanjing IASO Biotechnology Co., Ltd.. CAR-T cell therapy targets CD19-positive B cells

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eque-cel CAR-T Therapy TARGET	Eque-cel CAR-T Therapy	Nanjing IASO Biotechnology Co., Ltd.	phase 2	CAR-T cell therapy	CD19
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)
REZ	REZ	Centers for Disease Control and Prevention	marketed	Monoclonal antibody	CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy class)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 3 drugs in this class
Chongqing Precision Biotech Co., Ltd · 2 drugs in this class
Guangzhou Women and Children's Medical Center · 2 drugs in this class
Sinocelltech Ltd. · 2 drugs in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Guangzhou Bio-gene Technology Co., Ltd · 1 drug in this class
Celyad Oncology SA · 1 drug in this class
Janssen Scientific Affairs, LLC · 1 drug in this class
EdiGene Inc. · 1 drug in this class
Hrain Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eque-cel CAR-T Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/eque-cel-car-t-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing